92 SAFETY, TOLERABILITY AND ANTIVIRAL ACTIVITY OF VCH-916, A NOVEL NON-NUCLEOSIDE HCV POLYMERASE INHIBITOR IN PATIENTS WITH CHRONIC HCV GENOTYPE-1 INFECTION

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Journal of Hepatology

• Publication date

  2009-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0168-8278(09)60094-5
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• No references are available for this paper.

• Direct-acting antivirals for chronic hepatitis C.

  2017cites this paper
• Direct-acting antivirals for chronic hepatitis C.

  2017cites this paper
• New therapeutic strategies in HCV: polymerase inhibitors

  2013cites this paper
• RNA dependent RNA polymerase of HCV: a potential target for the development of antiviral drugs.

  2013cites this paper
• Antiviral strategies in hepatitis C virus infection.

  2012cites this paper
• Stratégies antivirales dans l’hépatite chronique C

  2012cites this paper
• The HCV NS5B nucleoside and non-nucleoside inhibitors.

  2011cites this paper
• New hepatitis C therapies in clinical development

  2011cites this paper
• Quinoxalin-2(1H)-one derivatives as inhibitors against hepatitis C virus.

  2011cites this paper
• New HCV therapies on the horizon.

  2011cites this paper
• RNA-dependent RNA polymerases from different hepatitis C virus genotypes reveal distinct biochemical properties and drug susceptibilities.

  2011cites this paper
• Resistance to direct antiviral agents in patients with hepatitis C virus infection.

  2010cites this paper
• New treatments for chronic hepatitis C

  2010cites this paper
• 1a/1b Subtype Profiling of Nonnucleoside Polymerase Inhibitors of Hepatitis C Virus

  2010cites this paper
• Development of novel antiviral therapies for hepatitis C virus

  2010cites this paper
• Antiviral Therapy for Hepatitis C Virus: Beyond the Standard of Care

  2010cites this paper
• New NS5B polymerase inhibitors for hepatitis C

  2010cites this paper
• New therapies in the management of hepatitis C virus

  2010cites this paper
• Review: New direct-acting antivirals in the development for hepatitis C virus infection

  2010cites this paper
• Investigational drugs for hepatitis C

  2010cites this paper
• Non-nucleoside inhibitors of hepatitis C virus polymerase: current progress and future challenges.

  2010cites this paper
• Current and future treatment options for HCV.

  2009cites this paper
• REVIEWS IN BASIC AND CLINICAL GASTROENTEROLOGY

  2009cites this paper
• The Potential for Combination Treatment Using STAT-C Drugs

  2009cites this paper